Pfizer and Glenmark Pharmaceuticals (Glenmark) have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India.
Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.
When launched in India, it will be co‐marketed under the brand names JABRYUS® and CIBINQO® by Glenmark and Pfizer respectively. This collaboration combines the expertise of the companies to offer a groundbreaking treatment for moderate‐to‐severe AD, with improved efficacy and oral convenience to patients. Abrocitinib (CIBINQO) is available in over 35 markets globally, including the U.S., Japan, and China.
Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects 1,2. The persistent itching associated with moderate‐to‐severe AD disrupts daily life, impacting social interactions, work productivity, and overall well‐being. Abrocitinib, a Janus kinase 1 (JAK1) inhibitor, providesrapid itch relief, sustained disease control, and a vastly improved quality of life for patient |